SCHEMBL568610

SCHEMBL568610

COC(=O)C(C)(C)[C@](C)(N[S@@+]([O-])C(C)(C)C)c1ccccc1F

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPSR1 Q6W5P4 1/20 0.38
BACE1 P56817 1/20 0.36
KCNN4 O15554 6/20 0.33
HDAC6 Q9UBN7 2/20 0.33
HDAC3 O15379 1/20 0.33
HDAC1 Q13547 1/20 0.33
HDAC2 Q92769 1/20 0.33
ELANE P08246 1/20 0.32
CYP3A4 P08684 1/20 0.32
GAA P10253 1/20 0.32
MAPT P10636 1/20 0.32
CYP2C9 P11712 1/20 0.32
ALOX12 P18054 1/20 0.32
CYP2C19 P33261 1/20 0.32
MEN1 O00255 2/20 0.32
KMT2A Q03164 2/20 0.32
SRC P12931 1/20 0.31
PLCG1 P19174 1/20 0.31
PDK1 Q15118 1/20 0.31
PDK2 Q15119 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL569019 0.83 PTGDR2 (0.32) BACE1KMT2ASMN1; SMN2
SCHEMBL20560486 0.80 BACE1 (0.39) BACE1KCNN4HDAC6HDAC3HDAC1
SCHEMBL17006967 0.80 BACE1 (0.39) BACE1KCNN4HDAC6HDAC3HDAC1
SCHEMBL20560485 0.80 BACE1 (0.39) BACE1KCNN4HDAC6HDAC3HDAC1
SCHEMBL15903389 0.80 BACE1 (0.39) BACE1KCNN4HDAC6HDAC3HDAC1
SCHEMBL287144 0.80 HTT (0.41) NPSR1GAAMAPTCYP2C19MEN1
SCHEMBL287142 0.80 HTT (0.41) NPSR1GAAMAPTCYP2C19MEN1
SCHEMBL287143 0.80 HTT (0.41) NPSR1GAAMAPTCYP2C19MEN1
SCHEMBL12981375 0.79 TAAR1 (0.38) NPSR1BACE1GAAMAPTCYP2C19
SCHEMBL2591955 0.79 TAAR1 (0.40) NPSR1BACE1GAAMAPTCYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20140336208-A1 1,4,5,6-TETRAHYDRO-PYRIMIDIN-2-YLAMINE COMPOUNDS F. HOFFMANN-LA ROCHE AG (CH) 2014-11-13 US disclosed
US-8815881-B2 1,4,5,6-tetrahydro-pyrimidin-2-ylamine compounds HOFFMANN-LA ROCHE INC. (US) 2014-08-26 US disclosed
EP-2603496-A1 1,4,5,6-TETRAHYDRO-PYRIMIDIN-2-YLAMINE COMPOUNDS F.HOFFMANN-LA ROCHE AG (CH) 2013-06-19 EP disclosed
WO-2012019966-A1 1,4,5,6-TETRAHYDRO-PYRIMIDIN-2-YLAMINE COMPOUNDS F. HOFFMANN-LA ROCHE AG (CH) 2012-02-16 WO disclosed
US-20120035195-A1 1,4,5,6-TETRAHYDRO-PYRIMIDIN-2-YLAMINE COMPOUNDS SIENA BIOTECH S.P.A., AN ITALIAN COMPANY (IT) 2012-02-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140336208-A1 1,4,5,6-TETRAHYDRO-PYRIMIDIN-2-YLAMINE COMPOUNDS BACE2, BACE1, PSEN2 NPSR1 1906/4885BACE1 2/4885KCNN4 3324/4885
US-20120035195-A1 1,4,5,6-TETRAHYDRO-PYRIMIDIN-2-YLAMINE COMPOUNDS BACE2, BACE1, PSEN2 NPSR1 1906/4885BACE1 2/4885KCNN4 3324/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.